CATX ▲ +0.4% - Perspective Therapeutics, Inc.
$CATX - Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-?-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs
23-OCT-2026 10:49 AM ET
Share this post
More filings for $CATX
CATX ▲ +2.8% - Perspective Therapeutics, Inc.Oct 8, 2026CATX - Perspective Therapeutics, Inc. - SEC Filing Update (23-SEP-2026) | ThinkSabio - Stocks SimplifiedSep 23, 2026CATX ▲ +6.4% - Perspective Therapeutics, Inc.Sep 14, 2026CATX - Perspective Therapeutics, Inc. - SEC Filing Update (04-SEP-2026) | ThinkSabio - Stocks SimplifiedSep 4, 2026CATX - Perspective Therapeutics, Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026CATX - Perspective Therapeutics, Inc. - SEC Filing Update (07-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 7, 2026
View full $CATX filing history →💬 Comments
Loading comments…
Leave a comment